| X-CLX-Shades: |
MLX |
| X-CLX-Response: |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 |
| Date: |
Wed, 19 Jun 2024 13:07:40 +0200 |
| Reply-To: |
|
| Approved-By: |
|
| Message-ID: |
|
| MIME-Version: |
1.0 |
| Subject: |
|
| Emisor: |
|
| Received: |
by LISTSERV.REDIRIS.ES (LISTSERV-TCP/IP release 17.0) with spool id
9774429 for [log in para visualizar]; Wed, 19 Jun 2024
13:08:01 +0200
from mx08-006a4e02.pphosted.com (mx08-006a4e02.pphosted.com
[143.55.148.243]) by listserv.backend.rediris.es (Postfix) with ESMTP
id BA3BF1E958E for < [log in para visualizar]>; Wed, 19 Jun
2024 13:07:43 +0200 (CEST)
from pps.filterd (m0316694.ppops.net [127.0.0.1]) by
m0316694.ppops.net (8.17.1.24/8.17.1.24) with ESMTP id 45JAuDxD001100
for < [log in para visualizar]>; Wed, 19 Jun 2024 13:07:43 +0200
from satellite01.sim.rediris.es (satellite01.sim.rediris.es
[130.206.24.60]) by m0316694.ppops.net (PPS) with ESMTPS id
3yuj8ehqpv-1 (version=TLSv1.2 cipher=ECDHE-RSA-AES256-GCM-SHA384
bits=256 verify=NOT) for < [log in para visualizar]>; Wed, 19
Jun 2024 13:07:41 +0200 (MEST)
from satellite01.sim.rediris.es (localhost.localdomain [127.0.0.1])
by satellite01.sim.rediris.es (Postfix) with ESMTPS id 30FC58171F for
< [log in para visualizar]>; Wed, 19 Jun 2024 13:07:41 +0200
(CEST)
from localhost (localhost.localdomain [127.0.0.1]) by
satellite01.sim.rediris.es (Postfix) with ESMTP id 2B3C28171C for
< [log in para visualizar]>; Wed, 19 Jun 2024 13:07:41 +0200
(CEST)
from satellite01.sim.rediris.es ([127.0.0.1]) by localhost
(satellite01.sim.rediris.es [127.0.0.1]) (amavis,
port 10026) with ESMTP id KkzR2bm5xYmQ for
< [log in para visualizar]>; Wed, 19 Jun 2024 13:07:41 +0200
(CEST)
from web-node01.backend.rediris.es (web-node01.backend.rediris.es
[130.206.25.31]) by satellite01.sim.rediris.es (Postfix) with ESMTP
id 1275F80F22 for < [log in para visualizar]>; Wed, 19 Jun 2024
13:07:41 +0200 (CEST)
by web-node01.backend.rediris.es (Postfix,
from userid 48) id F384385D44; Wed, 19 Jun 2024 13:07:40 +0200 (CEST) |
| Content-Type: |
text/plain; charset=UTF-8; |
| X-Amavis-Modified: |
Mail body modified (using disclaimer) -
satellite01.sim.rediris.es |
| Delivered-To: |
|
| X-Proofpoint-ORIG-GUID: |
DdyBQY-ce3m0VL4AavHMCZ_I5Ek1QGR_ |
| Sender: |
|
| X-Proofpoint-Spam-Details: |
rule=politica_listserv_notspam
policy=politica_listserv score=38 impostorscore=0
adultscore=0 spamscore=38 bulkscore=0 clxscore=179
lowpriorityscore=0 priorityscore=0 mlxscore=38
phishscore=0 mlxlogscore=22 suspectscore=0
malwarescore=0 classifier=spam adjust=0 reason=mlx
scancount=1 engine=8.19.0-2405170001
definitions=main-2406190083 domainage_hfrom=1401 |
| X-Proofpoint-Virus-Version: |
vendor=baseguard
engine=ICAP:2.0.293,Aquarius:18.0.1039,Hydra:6.0.680,FMLib:17.12.28.16
definitions=2024-06-19_02,2024-06-19_01,2024-05-17_01 |
| X-Proofpoint-GUID: |
DdyBQY-ce3m0VL4AavHMCZ_I5Ek1QGR_ |
| Parts/Attachments: |
|
|
===
Para darse de ALTA/BAJA del Boletin OFER-TRABEC utilice el siguiente enlace o pongase en contacto con [log in para visualizar]
https://listserv.rediris.es/cgi-bin/wa?SUBED1=OFER-TRABEC&A=1
===
SEGURIDAD: Los enlaces contenidos en este mensaje son seguros y protegidos con reescritura de URL_DEFENSE de Proofpoint
===
---Procedencia:
Institución:IIS Aragon (Zaragoza)
Contacto correo-e:[log in para visualizar]
---
Project Summary:
In Spain, between 20-25% of livers and kidneys donated for transplantation are currently wasted due to problems such as hepatic steatosis (>30%) or prolonged warm ischemia (>2h). However, recent advances in dynamic normothermic machine perfusion (NMP) have made it possible to maintain these organs in conditions closer to their natural physiologic microenvironment. Prolonged NMP in the liver (and kidney) opens the door to the regeneration of marginal organs before transplantation. Thus, our proposal focuses on the development of ex vivo cell therapy with mesenchymal stem cells (MSCs) applied to marginal organs, such as steatotic livers and kidneys with prolonged ischemia, that have been previously rejected for transplantation. This procedure will be carried out using state-of-the-art technology. Subsequently, human marginal organs regenerated by this advanced therapy under prolonged NMP conditions will be transplanted into immunodeficient pigs (SCID) to assess their survival, viabilit
y, and medium-term function. The success of this project will boost the adoption of organ regeneration techniques using NMP and ex vivo cell therapy, which could significantly increase the global availability of livers and kidneys for transplantation, with a special focus on meeting the needs of elderly patients suffering from chronic and oncological diseases.
Who we are:
We are a consolidated multidisciplinary research team (Digestive Pathology and Hepatology Research Group, led by Dr. Angel Lanas) with one of Aragon's highest publication impact factors. The work will be done at the Organ Bioengineering and Regenerative Medicine Laboratory led by Dr. Pedro Baptista.
We are located at the Health Research Institute of Aragon (IIS Aragon), right between the two University Hospitals in Zaragoza and at one of the campuses of the University of Zaragoza, by the side of the School of Medicine. Our institute provides cutting edge facilities for cell culture, bioengineering lab, flow cytometry, experimental surgery, microscopy, genomics, proteomics and a state-of-the-art animal facility, all integrated into one facility.
Zaragoza, also known in English as Saragossa, is the capital city of the Zaragoza province and of the autonomous community of Aragon, Spain. It is a vibrant and dynamic city, full of opportunities and rich in history and culture, with a great quality of life.
----------------
Información complementaria de la oferta:
What we offer:
2-year full-time contract (6 months trial period) with the chance for long-term stabilization at the collaborating company EBERS Medical SL, or apply to competitive grants at IIS Aragon (Marie Curie, Sara Borrell, Miguel Servet) for a longer/permanent time.
Flexible working hours.
Multidisciplinary environment.
International networking opportunities.
Soft-skills development.
What your tasks will be:
Run the ex vivo normothermic perfusion experiments with kidneys and livers in EBERS Medical machine.
Isolate, expand and characterize porcine and human mesenchymal stem cells.
Help with the procurement and transplantation of the ex vivo regenerated organs.
Present data in regular-based meetings, writing
reports and manuscripts.
Job requirements:
PhD in science or equivalent academic degree in:
Biomedical Engineering, Biology, Medicine, Pharmacy, Biochemistry, or similar.
English language fluency
Experience in:
- hMSC isolation, expansion and characterization.
- normothermic machine perfusion of solid organs.
- Cell culture, molecular biology, microscopy and histology.
- Strong scientific production that allows applying for other competitive national and international postdoctoral fellowships.
Conditions of the employment:
A standard postdoc contract (2 year), with a salary of 34,000 €/year.
The post is immediately available. Later dates can be considered.
How to apply?
https://en.iisaragon.es/ofertas_de_empleo/doctor-a-isciii-ref-iis40-24/
Email: [log in para visualizar]
The application deadline is June 28, 2024.
|